1. Ho MP, Gonzalez JM, Lerner HP, et al. Incorporating patient preference evidence into regulatory decision making. Surg Endosc. 2015;29(10):2984–93.
2. Al-Faruque F. FDA weighs patients’ risk tolerance in approving obesity device. The Pink Sheet; 2015 Jan 20.
https://pink.pharmaintelligence.informa.com/PS077790/FDA-Weighs-Patients-Risk-Tolerance-in-Approving-Obesity-Device
. Accessed 29 Jun 2019.
3. US Food and Drug Administration. Patient preference information—voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling: guidance for industry, Food and Drug Administration staff, and other stakeholders. 2016.
https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM446680.pdf
. Accessed 27 Dec 2018.
4. US Food and Drug Administration. Plan for issuance of patient-focused drug development guidance under 21st Century Cures Act Title III Section 3002. 2017.
https://www.fda.gov/media/105979/download
. Accessed 29 Jun 2019.
5. US Food and Drug Administration. Benefit-risk assessment throughout the drug lifecycle: FDA discussion document. 2019.
https://healthpolicy.duke.edu/sites/default/files/atoms/files/discussion_guide_b-r_assessment_may16_0.pdf
. Accessed 29 Jun 2019.